Synthomer's trailing twelve-month price-to-earnings ratio reflects an "at loss" status due to recent periods of negative net earnings per share, though forward-looking valuation metrics fluctuate depending on projected recovery milestones and shifting share prices on the London Stock Exchange. Investors evaluating turnaround equities often look beyond traditional P/E multiples, focusing instead on enterprise value-to-EBITDA ratios, balance sheet deleveraging progress, and operating cash flow trends.